Arena Pharmaceuticals Inc
ARNA
ARNA was delisted on the 10th of March, 2022.
165 hedge funds and large institutions have $1.75B invested in Arena Pharmaceuticals Inc in 2018 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 69 increasing their positions, 51 reducing their positions, and 25 closing their positions.
35% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 51
15% more capital invested
Capital invested by funds: $1.53B → $1.75B (+$225M)
3% less funds holding
Funds holding: 170 → 165 (-5)
12% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 25
18% less call options, than puts
Call options by funds: $34.8M | Put options by funds: $42.5M
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$51.4M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$44.3M |
| 3 |
PA
Perceptive Advisors
New York
|
+$28.8M |
| 4 |
BlackRock
New York
|
+$22.8M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$22.7M |
Top Sellers
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$43.1M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$38.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$34.2M |
| 4 |
Millennium Management
New York
|
-$13.5M |
| 5 |
DM
Deerfield Management
New York
|
-$12.9M |
ARNA Hedge Fund Activity: Q2 2018 in Review
165 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Arena Pharmaceuticals Inc (ARNA) for Q2 2018, worth a combined $1.75B — up 15% from $1.53B a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ARNA and 22 opened new positions — a net loss of 3 holders — while 51 trimmed existing stakes and 69 added.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $51.4M. The largest seller was Great Point Partners, cutting an estimated $43.1M.
- 165 institutional investors held Arena Pharmaceuticals Inc (ARNA) as of Q2 2018, down from 170 in Q1 2018.
- Funds reported $1.75B of Arena Pharmaceuticals Inc stock for Q2 2018, up 15% quarter-over-quarter.
- 22 funds opened new Arena Pharmaceuticals Inc positions in Q2 2018 and 25 closed out, a net change of -3 holders.
- The largest Arena Pharmaceuticals Inc buyer in Q2 2018 was PFM Health Sciences, an estimated $51.4M added.
- The largest Arena Pharmaceuticals Inc seller in Q2 2018 was Great Point Partners, an estimated $43.1M sold.
Based on aggregated 13F filings for Q2 2018.